A stem cell biotech in the news this week was one that had mostly flown under the radar previously with aim to zap cancer stem cells. Stemcentrx has a focus on killing cancer stem cells as a novel approach to treating cancer. Antonio Regalado had a nice article yesterday on the company. He reports that Stemcentrx has […]
Can Stemcentrx thrive as a biotech killing cancer stem cells? Read More »
To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those
Tale of 7 stem cell biotech stock woes Read More »
The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors and biotech companies. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop fantastic science and then realise the most important components cannot be adapted to the clinical
Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc Read More »
Last week I attended Biotech & the Ethical Imagination (BEINGS 2015), the summit I previewed on this blog back in early May. It many ways the summit lived up to its lofty ambitions. Steven Pinker kicked off the event by emphasizing the power and importance of biomedical research, noting that almost everyone is affected by
Recap of BEINGS 2015 Meeting by Aaron Levine: Shaping Future of Cellular Biotech Read More »
Later this May, I will attend and participate in Biotechnology and the Ethical Imagination (BEINGS 2015). This is an exciting and experimental summit that will focus on advances in cellular biotechnology – including both stem cell science and synthetic biology. The meeting is premised on the idea that the implications of increasing biotechnology power are
Biotechnology & the Ethical Imagination – A Preview of BEINGS summit Read More »
A new biotech startup, Semma Therapeutics, announced that it seeks to fight diabetes via translating technology from the lab of Doug Melton at Harvard to the clinic. Update: Note that the firm was recently acquired by Vertex. Another major player in cell therapy-based arena for Diabetes is most likely good news for patients. Quoted in the Boston
New biotech Semma Therapeutics stem cell diabetes arena Read More »
The below is an excerpt from my book, Stem Cells: An Insider’s Guide. I hope you enjoy this excerpt and the book, which I think is a really good deal at under $27 paperback or under $17 for E-book version. Having our innovation and ethics too In the stem cell field you can have it
Book Excerpt: Stem Cell For-Profit Good Citizen Biotechs Read More »
What the heck is going on with Intellicell Biosystems, Inc. (SVFC, also SVFCE), a stem cell corporation run by Dr. Steven Victor? Why are some on Wall Street seeming so bullish on the company lately? What’s the real story and the facts? What is the key background on this company? Wall Street has been buying
Wall Street Weirdness Over Stem Cell Biotech Intellicell (SVFC) Read More »
What does it take to be a stem cell biotech CEO?I’ve been running a poll on what is the ideal background for the CEO of a stem cell company. We got a pretty good turnout in this poll, although one is to be reminded that Internet polls are not scientific. It’s not perfect, but the
Poll results on stem cell biotech CEO are interesting Read More »
For the second year in a row (see awards 2011), Advanced Cell Technology (ACT; stock symbol ACTC) is my stem cell biotech of the year. Their trials for different forms of macular degeneration (here and here and here) are progressing well and as a stem cell scientist I really appreciate the fact they are publishing their
Stem cell biotech of the year 2012: Advanced Cell Technology (ACTC) Read More »